What is CJC-1295 with DAC?
CJC-1295 with DAC combines GHRH receptor activity with an albumin-binding design. Its Drug Affinity Complex contains a reactive group that links the peptide to circulating albumin, changing how long the signal persists. This is a structural distinction from the no-DAC material, rather than simply another vial size of the same molecule.
The albumin-linked preparation retained biological activity in pituitary-cell experiments and produced prolonged endocrine exposure in animal work. Short human studies subsequently found sustained increases in growth hormone and IGF-I, with natural growth-hormone pulses still evident against a higher baseline. These observations make it useful for understanding the difference between signal duration and pulse structure. They concern defined study preparations; the clinical pharmacology does not establish the identity, salt form or performance of an independently supplied research batch.
Related scientific guides: CJC-1295 DAC and no-DAC structural distinctions.
CJC-1295 with DAC Research Areas
Albumin-conjugated GHRH analogues retained activity in pituitary cells and resisted degradation. The selected CJC-1295 preparation produced prolonged exposure and a larger growth-hormone response than the comparison fragment in rats. Its reactive albumin-binding group is therefore part of the mechanism and must be distinguished from no-DAC compounds.
Jetté et al. · Endocrinology · 2005PubMed
Growth hormone and IGF-I remained elevated for several days after DAC-bearing CJC-1295 in healthy adults. Two short, placebo-controlled studies estimated a half-life of roughly six to eight days, consistent with its albumin-binding design. The observations describe the DAC preparation’s pharmacology and do not supply a duration estimate for CJC-1295 without DAC.
Teichman et al. · J Clin Endocrinol Metab · 2006PubMed
Growth-hormone pulses remained evident during prolonged stimulation by CJC-1295 with DAC. Healthy men had higher trough and mean growth-hormone concentrations and higher IGF-I one week after administration, while pulse frequency and magnitude were unchanged. This distinguishes a raised endocrine baseline from an increase in pulse frequency, within one short observation window.
Ionescu et al. · J Clin Endocrinol Metab · 2006PubMed
Molecular profile
- Compound
- CJC-1295 with DAC
- Amount
- 5 mg
- Sequence
- Tyr-D-Ala-
Asp-Ala- Ile-Phe- Thr-Gln- Ser-Tyr- Arg-Lys- Val-Leu- Ala-Gln- Leu-Ser- Ala-Arg- Lys-Leu- Leu-Gln- Asp-Ile- Leu-Ser- Arg-Lys(3-maleimidopropionyl)-NH2 - Residue count
- 30
- Molecular formula
- C165H269N47O46
- Molecular weight
- 3647.2 g/mol
- CAS number
- 446262-90-4
- Chemical class
- Synthetic growth hormone-releasing hormone analogue with Drug Affinity Complex
- Classification
- Research peptide
- Parent molecule
- CJC-1295 with DAC
- Available vial sizes
- 5 mg
Analytical verification
- Lynx report reference
- UKLY-641
- Reported purity
- 98.65%
- Analysis method
- RP-HPLC + ESI-MS
- Identity result
- Confirmed: CJC-1295 DAC
- Analysis date
- 3 Sept 2026
- Report date
- 3 Sept 2026
Storage & Reconstitution
Store in appropriate cool, dry conditions. Refer to product-specific storage information when published.
Vials are supplied separately from bacteriostatic water and other preparation supplies.
For laboratory handling context, read Research peptide storage and stability. Product-specific information and the laboratory method take precedence.
For laboratory preparation, allow the sealed vial to reach room temperature before opening. Wipe the vial stopper and bacteriostatic-water stopper with an alcohol wipe. Add bacteriostatic water slowly down the inside wall of the vial, then swirl gently until dissolved. Do not shake.
Research literature
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Teichman et al. · J Clin Endocrinol Metab · 2006PubMed
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.Ionescu et al. · J Clin Endocrinol Metab · 2006PubMed
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Jetté et al. · Endocrinology · 2005PubMed
CJC-1295 with DAC Price (UK)
CJC-1295 with DAC is supplied in 5 mg vials for laboratory research. The current price is £41.99.
Current availability is shown below. UK orders of £49.99 or more qualify for free standard shipping. Eligible working-day orders placed before 4 PM are dispatched the same day.
| Vial size | Current price | Price / mg | Status |
|---|---|---|---|
| 5 mg | £41.99 | £8.40/mg | Checking stock |
Common questions about CJC-1295 with DAC
What is CJC-1295 with DAC?
CJC-1295 with DAC is a synthetic GHRH analogue with a Drug Affinity Complex modification. The peptide portion is studied for GHRH-receptor signalling, while the DAC feature enables binding to albumin. This combines a receptor-active design with a carrier-binding feature, allowing researchers to examine both biological activity and how long the analogue persists.
What does the DAC part do?
The DAC feature can attach the peptide to albumin, a large protein circulating in blood. Albumin binding changes the peptide's exposure profile, rather than adding another receptor target. This is why research on the with-DAC form considers its persistence alongside its GHRH activity, and distinguishes it from CJC-1295 without DAC.
How does CJC-1295 with DAC differ from CJC-1295 without DAC?
The with-DAC version includes an albumin-binding modification; the without-DAC form does not. Both relate to GHRH signalling, but the additional feature changes persistence in circulation. They are therefore different molecular forms, not simply stronger and weaker vials, and an exposure finding for one form cannot be assumed to apply to the other.
Is CJC-1295 with DAC used in the Lynx Ipamorelin blend?
No. The CJC-1295 + Ipamorelin blend uses CJC-1295 without DAC and adds a second peptide acting through the ghrelin receptor. This individual with-DAC product instead has an albumin-binding feature. The blend and this vial therefore differ in both composition and research design; combining two peptides does not recreate the DAC modification.
Why is albumin binding useful to study?
Albumin binding shows how attaching a peptide to a carrier protein changes its time in circulation. That is a different question from whether the peptide activates its receptor. Comparing those measurements helps explain why two related analogues can have similar receptor targets yet different exposure patterns, without assuming persistence automatically means a stronger receptor response.
Is albumin an ingredient in the CJC-1295 with DAC vial?
No. DAC is a feature of the peptide designed to bind albumin when that protein is present; it does not mean albumin is supplied in the vial. Receptor assays and albumin-binding experiments therefore examine different parts of the design. The proteins present in an experimental system matter when studying that binding behaviour.
Can I buy CJC-1295 with DAC in the UK for research?
Yes. Lynx lists CJC-1295 with DAC in 5mg vials for laboratory research, with UK fulfilment. This page shows whether that version is available to order.
How is CJC-1295 with DAC verified?
The 5mg CJC-1295 DAC certificate, UKLY-641, gives purity 98.65% using RP-HPLC + ESI-MS.
